Clinical Trial Update: Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma [Phase 1]

View source ↗

Summary

An ongoing Phase 1 trial evaluating OMTX705 in combination with gemcitabine/nab-paclitaxel and tislelizumab for advanced/metastatic pancreatic adenocarcinoma (r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• OMTX705 (OMTX705)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Oncomatryx Biopharma S.L. | Conditions: Pancreatic Adenocarcinoma Metastatic | Phase 1 | Status: RECRUITING